{
    "clinical_study": {
        "@rank": "15101", 
        "arm_group": {
            "arm_group_label": "Lansoprazole 15 mg", 
            "description": "Lansoprazole 15 mg orally once daily"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and efficacy of long-term\n      administration of lansoprazole (Takepron) therapy for up to 12 months in the routine\n      clinical setting in patients receiving oral non-steroidal anti-inflammatory drugs (NSAIDs)"
        }, 
        "brief_title": "Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric or Duodenal Ulcers", 
        "condition_browse": {
            "mesh_term": [
                "Duodenal Ulcer", 
                "Recurrence", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a special survey on long-term use (for up to 12 months) of lansoprazole (Takepron)\n      to determine the incidence of adverse drug reactions in the routine clinical setting in\n      patients receiving non-steroidal anti-inflammatory drugs (NSAIDs).\n\n      The usual adult dosage is 15 mg of lansoprazole administered orally once daily."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  (1) Patients with a history of gastric or duodenal ulcers (2) Patients requiring\n             long-term use of NSAIDs for reasons such as pain management for rheumatoid arthritis\n             or osteoarthritis (3) Patients taking oral NSAIDs at the start of administration of\n             lansoprazole (including patients who start NSAIDs on the same day as the start of\n             administration of lansoprazole)\n\n        Exclusion Criteria:\n\n          -  (1) Patients with gastric or duodenal ulcer (in the active [A1, A2] or healing [H1,\n             H2] stage if assessed endoscopically) at the start of administration of lansoprazole\n             (2) Patients with active upper gastrointestinal hemorrhage at the start of\n             administration of lansoprazole (3) Patients with contraindications for lansoprazole"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Gastric or duodenal ulcers"
            }
        }, 
        "enrollment": {
            "#text": "3502", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02099708", 
            "org_study_id": "467-713"
        }, 
        "intervention": {
            "arm_group_label": "Lansoprazole 15 mg", 
            "description": "Lansoprazole Capsules 15/ OD Tablets 15", 
            "intervention_name": "Lansoprazole", 
            "intervention_type": "Drug", 
            "other_name": "Takepron Capsules 15, Takepron OD Tablets 15"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Inflammatory Agents", 
                "Anti-Inflammatory Agents, Non-Steroidal", 
                "Lansoprazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacological therapy", 
        "lastchanged_date": "March 26, 2014", 
        "number_of_groups": "1", 
        "official_title": "Takepron Capsules 15/ Orally Dispersing\uff08OD\uff09 Tablets 15 Special Drug Use Surveillance Long-term Use Survey on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Frequency, severity, and time to onset of adverse drug reactions tabulated by each symptom. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions..", 
            "measure": "Frequency of adverse drug reactions", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02099708"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Summary of data on the presence or absence of endoscopic examinations, onset of gastric or duodenal ulcers, onset of gastric or duodenal hemorrhagic lesions, and details of treatment and outcome of treatment for gastric or duodenal ulcers or hemorrhagic lesions.", 
            "measure": "Onset of gastric or duodenal ulcers or hemorrhagic lesions after the start of administration of lansoprazole", 
            "safety_issue": "No", 
            "time_frame": "From baseline to 12 months"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}